Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Tien-Li Lee
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Beta
- 3.81
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 5.49
Financials
Net Income
$-14.39MEBITDA
$-14.39MFree Cash Flow
$-17.60MEPS (diluted)
$-0.66Shares Outstanding (diluted)
21.85M+2.2%Operating Expenses
$15.08MCash & Debt
$73.87MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-57.59M | $-2.64 |
| 2024 | $0.00 | $-20.59M | $-0.95 |
| 2023 | $0.00 | $-7.21M | $-0.34 |
| 2022 | $0.00 | $-13.56M | $-0.63 |
Valuation
AARDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-50.00%Social Signal Score
Mentions (9)
- Newsprnewswire.com·10d ago·Negative
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM TOWNSHIP, Pa., Sept. 25, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Lowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for Potential Violations of the Federal Securities Laws NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C.
View source ↗ - Newsprnewswire.com·24d ago·Negative
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM, Pa., Sept. 11, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newsprnewswire.com·25d ago·Negative
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- The Law Offices of Frank R.
View source ↗ - Newsgurufocus.com·34d ago·Negative
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK,
View source ↗ - Newsprnewswire.com·38d ago·Negative
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM, Pa., Aug. 28, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newsprnewswire.com·46d ago·Negative
LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a deadline is coming up on October 31, 2026, in the lawsuit that was filed for certain investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD). Investors, who purchased shares in excess of $100,000 of Aardvark Therapeutics, Inc. (NASDA…
View source ↗ - Newsbusinesswire.com·47d ago·Negative
Securities Fraud Investigation Into Aardvark Therapeutics, Inc. (AARD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON AARDVARK THERAPEUTICS, INC. (AARD), C…
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.74 per share
Typical surprise -5.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.66 vs $-0.87beat
- Thu, May 7$-0.99 vs $-0.88miss
- Mon, Mar 23$-0.81 vs $-0.83beat
- Thu, Nov 13$-0.75 vs $-0.80beat
- Wed, Aug 13$-0.66 vs $-0.60miss
- Wed, May 14$-0.71 vs $-0.67miss
Estimates and results for AARD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AARD officers and directors.
- Bought
- $24.4m
- Sold
- $395k
22 trades
2 trades
- Sun Nelsonsold
- Sun Nelsonsold
- Sun Nelsonbought
- Lee Tien-liboughtdirector, 10 percent owner, officer: Chief Executive Officer·7,000 @ $14.48·$101k·Dec 11, 2025·filing
- Lee Tien-libought
- Lee Tien-libought
- Lee Tien-libought
- Lee Tien-libought
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AARD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.